Optimized and scalable LNP composition for RNA vaccine delivery

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Optimized and scalable LNP composition for RNA vaccine delivery

Lipid nanoparticle encapsulated RNA (RNA-LNP) vaccines have played a pivotal role in the global response to the COVID-19 pandemic and are now gaining momentum against various other infectious diseases. But diving into the world of LNPs means facing obstacles, particularly the limited access to potent ionizable lipids, a key component for LNPs. Considerable expertise in formulation and scale-up is also required. These issues present barriers to entry into the field.

To overcome these challenges, a novel ionizable lipid and corresponding LNP composition has been developed for the delivery of RNA in vaccine applications, accelerating payload screening and LNP optimization. In this webinar, we will discuss the optimization of a potent RNA-LNP vaccine composition demonstrating in vivo immunogenicity across various infectious diseases.

Attend the webinar to:

Understand the current landscape of genomic medicines and vaccines
Gain insights into LNP formulation and physicochemical characteristics with both mRNA and saRNA
Explore in vivo immunogenicity of RNA-LNP vaccines against influenza A and SARS-CoV-2
Discover how to overcome scale-up challenges in vaccine development

Martin Rabel

Services Solution Specialist at Cytiva

Martin Rabel, Dipl.-Pharm., Ph.D. currently works as a Services Solution Specialist for Cytiva supporting clients in Central Europe, Middle East, and Africa (EMEA). He obtained his pharmaceutical license as well as a postgraduate diploma from the Friedrich-Schiller-University Jena working on Bacterial Nanocellulose (BNC) nanoparticles for gene delivery applications. His Ph.D. research focused on the development of animal-free simulation models for the development of complex diagnostic nanoparticles (IONP) and other nanomedicines as well as nanoparticle characterization and manufacturing methods. He specializes in the development of novel nanomedicines using the NanoAssemblrTM platform and gene delivery reagents. His expertise spans formulation development, optimization as well as scale-up including GMP manufacturing.